ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

Drug Shortage A Boon For Levoleucovorin; Price Is 60 Times Higher Than Leucovorin

January 16, 2009

MSKCC Asked To Repay $638,371 To NIH

December 13, 1985

New Law Allows Texans To Self-Refer To M.D. Anderson

December 1, 1995

Corrections Made To NCI Phone Directory

May 17, 1991

Some Children With Hodgkin’s Disease Can Reduce Or Skip Radiation, Study Finds

October 29, 2004

HCFA Sees Applications For DRGs And Research

September 27, 1985